Vor Biopharma Expands Telitacicept Trials into Ocular Myasthenia…

Event summary

Vor Biopharma completed enrollment in its global Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis (gMG).
Topline results from the 24-week primary endpoint are expected in the first half of 2027.
The company plans to initiate a global Phase 3 trial (UPSTREAM oMG) for ocular myasthenia gravis, with first patient dosing anticipated in the first half of 2027.
Telitacicept is designed to treat autoimmune diseases through dual inhibition of BAFF and APRIL, targeting B-cell modulation.

The big picture

Vor Biopharma's expansion into ocular myasthenia gravis with telitacicept reflects a strategic push to broaden its autoimmune disease portfolio. The company is leveraging its existing Phase 3 data in generalized myasthenia gravis to support potential label expansions, positioning telitacicept as a foundational therapy across the myasthenia gravis spectrum. This move aligns with broader industry trends toward targeted B-cell modulation therapies, which aim to reduce autoantibody production while minimizing side effects.

What we're watching

Regulatory Pathway: Whether Vor Biopharma can secure regulatory approvals for telitacicept in the U.S., Europe, and Japan based on the upcoming trial results.
Market Expansion: The pace at which Vor Biopharma can expand telitacicept's global franchise into other autoimmune diseases beyond myasthenia gravis.
Competitive Positioning: How telitacicept's differentiated mechanism of action will position it against existing therapies in the myasthenia gravis market.